Viart N, Renault A, Eon-Marchais S, Jiao Y, Fuhrmann L, El Houdigui S
Breast Cancer Res. 2025; 27(1):36.
PMID: 40069712
PMC: 11899765.
DOI: 10.1186/s13058-025-01988-w.
Naeem W, Nawab F, Sarwar M, Khalil A, Gaber D, Ahmad H
Sci Rep. 2025; 15(1):7896.
PMID: 40050371
PMC: 11885471.
DOI: 10.1038/s41598-025-91700-x.
Ampolini E, Jimenez-Sainz J, Long D
Target Oncol. 2025; .
PMID: 40024979
DOI: 10.1007/s11523-025-01136-6.
Sweatman E, Bayley R, Selemane R, Higgs M
Br J Cancer. 2025; .
PMID: 39994444
DOI: 10.1038/s41416-025-02963-0.
Li H, Furusawa T, Cavero R, Xiao Y, Chari R, Wu X
Redox Biol. 2025; 80:103503.
PMID: 39854937
PMC: 11795153.
DOI: 10.1016/j.redox.2025.103503.
Association of Germline Pathogenic Variants in and Other DNA Damage Response Genes With Lung Cancer Risk Among Non-Hispanic Whites and African Americans.
Trendowski M, Lusk C, Wenzlaff A, Neslund-Dudas C, Purrington K, Beebe-Dimmer J
JCO Precis Oncol. 2025; 9():e2400558.
PMID: 39854657
PMC: 11771983.
DOI: 10.1200/PO-24-00558.
Potentially actionable molecular alterations in particular related to poor oncologic outcomes in salivary gland carcinomas.
Pikul J, Machnicki M, Rzepakowska A, Winiarska N, Chudy A, Moskowicz A
BMC Cancer. 2025; 25(1):42.
PMID: 39780157
PMC: 11708168.
DOI: 10.1186/s12885-024-13421-0.
Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors.
Zhao J, Zhu J, Tang Y, Zheng K, Li Z
Front Oncol. 2024; 14:1463892.
PMID: 39697230
PMC: 11652375.
DOI: 10.3389/fonc.2024.1463892.
Tumor sequencing before and after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: Genetic tumor characterization and clinical outcome.
Clasen K, Ballin N, Schutz L, Bonzheim I, Kelemen O, Orth M
Clin Transl Radiat Oncol. 2024; 50:100894.
PMID: 39670057
PMC: 11636126.
DOI: 10.1016/j.ctro.2024.100894.
Ferroptosis and its implications in bone-related diseases.
Wang Z, Yan Q, Wang Z, Hu Z, Wang C, Zhang X
PeerJ. 2024; 12:e18626.
PMID: 39619200
PMC: 11606331.
DOI: 10.7717/peerj.18626.
Breast cancer and ATM mutations: treatment implications.
Seca M, Narod S
Hered Cancer Clin Pract. 2024; 22(1):26.
PMID: 39543654
PMC: 11566136.
DOI: 10.1186/s13053-024-00300-9.
Somatic gene mutations involved in DNA damage response/Fanconi anemia signaling are tissue- and cell-type specific in human solid tumors.
Rai S, Du W, Zhang J, Yu H, Deng Y, Fei P
Front Med (Lausanne). 2024; 11:1462810.
PMID: 39421870
PMC: 11483370.
DOI: 10.3389/fmed.2024.1462810.
Double Hit in Clear-Cell Renal Cell Carcinoma With Germline Pathogenic ATM Mutation and Somatic VHL Mutation.
Chan K, Clavijo N, Ayala G, Hall R, Wray C, Cen P
J Investig Med High Impact Case Rep. 2024; 12:23247096241286370.
PMID: 39369320
PMC: 11457202.
DOI: 10.1177/23247096241286370.
DNA damage response in breast cancer and its significant role in guiding novel precise therapies.
Li J, Jia Z, Dong L, Cao H, Huang Y, Xu H
Biomark Res. 2024; 12(1):111.
PMID: 39334297
PMC: 11437670.
DOI: 10.1186/s40364-024-00653-2.
DNA damage response-related ncRNAs as regulators of therapy resistance in cancer.
Gao Z, Luan X, Wang X, Han T, Li X, Li Z
Front Pharmacol. 2024; 15:1390300.
PMID: 39253383
PMC: 11381396.
DOI: 10.3389/fphar.2024.1390300.
Star wars against leukemia: attacking the clones.
Toma M, Skorski T
Leukemia. 2024; 38(11):2293-2302.
PMID: 39223295
PMC: 11519008.
DOI: 10.1038/s41375-024-02369-6.
Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin.
Nishijima A, Oda K, Hasegawa K, Koso T, Asada K, Ikeda Y
Sci Rep. 2024; 14(1):18797.
PMID: 39138354
PMC: 11322660.
DOI: 10.1038/s41598-024-69796-4.
Genomic profiling of thymoma using a targeted high-throughput approach.
Peric J, Samaradzic N, Skodric Trifunovic V, Tosic N, Stojsic J, Pavlovic S
Arch Med Sci. 2024; 20(3):909-917.
PMID: 39050176
PMC: 11264071.
DOI: 10.5114/aoms.2020.96537.
Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on drug response genes to predict prognosis and therapeutic response in ovarian cancer.
Zhang Z, Chen M, Peng X
Heliyon. 2024; 10(13):e33367.
PMID: 39040239
PMC: 11260940.
DOI: 10.1016/j.heliyon.2024.e33367.
RNA demethylase FTO participates in malignant progression of gastric cancer by regulating SP1-AURKB-ATM pathway.
Zeng X, Lu Y, Zeng T, Liu W, Huang W, Yu T
Commun Biol. 2024; 7(1):800.
PMID: 38956367
PMC: 11220007.
DOI: 10.1038/s42003-024-06477-y.